Aileron Therapeutics, Inc. (NASDAQ:ALRN) has been assigned an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus target price of $19.33 for the company, according to Zacks. Zacks has also given Aileron Therapeutics an industry rank of 108 out of 265 based on the ratings given to its competitors.

A number of brokerages have issued reports on ALRN. Canaccord Genuity reaffirmed a “buy” rating and issued a $19.00 target price on shares of Aileron Therapeutics in a research report on Friday, August 11th. Bank of America Corporation began coverage on Aileron Therapeutics in a research report on Monday, July 24th. They issued a “buy” rating and a $19.00 target price on the stock. William Blair began coverage on Aileron Therapeutics in a research report on Monday, July 24th. They issued an “outperform” rating on the stock. Finally, Jefferies Group LLC began coverage on Aileron Therapeutics in a research report on Monday, July 24th. They issued a “buy” rating and a $20.00 target price on the stock.

Aileron Therapeutics (NASDAQ ALRN) traded up 4.81% on Friday, reaching $12.20. 20,179 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $12.38 and a 200-day moving average price of $12.56. The company’s market capitalization is $179.52 million. Aileron Therapeutics has a 1-year low of $10.37 and a 1-year high of $14.66.

In other news, major shareholder Cvf, Llc purchased 180,000 shares of the stock in a transaction dated Wednesday, July 5th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $2,700,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Reinhard J. Ambros purchased 266,667 shares of the stock in a transaction dated Wednesday, July 5th. The stock was purchased at an average price of $15.00 per share, with a total value of $4,000,005.00. The disclosure for this purchase can be found here. Insiders bought a total of 696,667 shares of company stock valued at $10,450,005 over the last quarter. Company insiders own 68.10% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ALRN. Jennison Associates LLC bought a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $2,788,000. Candriam Luxembourg S.C.A. bought a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $1,673,000. Sphera Funds Management LTD. bought a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $1,394,000. Nexthera Capital LP bought a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $1,272,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $418,000. Institutional investors and hedge funds own 12.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/15/zacks-aileron-therapeutics-inc-alrn-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.